Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Frova sNDA not approvable

Vernalis (LSE:VER) was off 20.5p (51%) to 20p on Monday after it and partner Endo (ENDP)

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE